Drug Trial Radar · NCT00384930
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Last checked: Nov 19, 2026Latest source record: Sep 2, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,058
Actual
Start
Aug 2006
Primary completion
Oct 2007
Study completion Oct 2008
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- ICOS Corporation
- First posted
- Oct 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including lower urinary tract symptoms.
Conditions
- Benign Prostatic Hyperplasia
Interventions
tadalafilDrug
2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
tadalafilDrug
5 mg tadalafil tablet by mouth once a day for twelve weeks.
tadalafilDrug
10 mg tadalafil tablet by mouth once a day for twelve weeks.
tadalafilDrug
20 mg tadalafil tablet by mouth once a day for twelve weeks.
placeboDrug
Placebo tablet taken by mouth one a day for twelve weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary AnalysisTime frame: Baseline and 12 weeks
- Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive AnalysisTime frame: Baseline and 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Greenwood, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.